Different from the strategy used for brain tumor treatment, we demonstrated in the present study that both genetic deletion of or pharmacological inhibition of HDAC3 alone is sufficient to block prostate cancer cell growth in vitro and in vivo, highlighting the value of single‐agent targeting of HDAC3 for prostate cancer treatment. The gene discussed is HDAC3; the disease is prostate carcinoma.